インヒビターの有無にかかわらず、血友病AまたはBの場合のコンシズマブの効果に関する調査研究 (Explorer10)
インヒビターの有無にかかわらず血友病AまたはBの12歳未満の小児におけるコンシズマブ予防の有効性、安全性および薬物動態を調査する非盲検試験
This study will test how well a new medicine called concizumab works for participants who have haemophilia A or B with or without inhibitors. The purpose is to show that concizumab can prevent bleeds and is safe to use.
Participants will have to inject the study medicine every day under the skin with a pen-injector.
The study will last for at least 2 years and up to about 4 years. The length of time the participant will be in the study depends on if the study medicine will be available for purchase in their country.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 3
アクセスの拡大
連絡先と場所
研究場所
-
-
California
-
San Diego、California、アメリカ、92123
- Rady Childrens Hosp San Diego
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- University of Colorado Hospital
-
-
Florida
-
Orlando、Florida、アメリカ、32806
- Arnold Palmer Children's Hospital
-
Orlando、Florida、アメリカ、32827
- Nemours Child Orlando Hem/Onc.
-
-
Georgia
-
Augusta、Georgia、アメリカ、30912
- Augusta Univ/Childrens Hosp-GA
-
Savannah、Georgia、アメリカ、31404
- Memorial Health University Medical Center
-
-
Illinois
-
Chicago、Illinois、アメリカ、60611
- Childrens Hospital of Chicago
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46260
- Indiana Hemophilia-Thromb Ctr
-
-
Louisiana
-
New Orleans、Louisiana、アメリカ、70121
- Ochsner Clinic Foundation
-
New Orleans、Louisiana、アメリカ、70118
- Children's Hosp-New Orleans
-
-
Missouri
-
Kansas City、Missouri、アメリカ、64108
- The Children's Mercy Hospital
-
-
Nebraska
-
Omaha、Nebraska、アメリカ、68114
- Children's Nebraska
-
-
North Carolina
-
Greenville、North Carolina、アメリカ、27834
- ECU Sickle Cell Comp Clinic
-
-
Ohio
-
Columbus、Ohio、アメリカ、43205
- Nationwide Children's Hospital
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19134
- St Christopher Hosp for Child
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37232
- Monroe Carell Jr. Children's Hospital at Vanderbilt
-
-
Texas
-
Fort Worth、Texas、アメリカ、76104
- Cook Children's Hospital-Hematology-Oncology
-
Houston、Texas、アメリカ、77030
- Texas Children's Hospital_Houston
-
-
Virginia
-
Charlottesville、Virginia、アメリカ、22908
- Pediatrics Hematology/Oncology Clinic Battle Building
-
-
-
-
-
Algiers、アルジェリア、16000
- Haematology and Blood Bank Department
-
Constantine、アルジェリア、25000
- CHU Constantine BEN BADIS/ Hematology department
-
-
-
-
-
Birmingham、イギリス、B4 6NH
- Birmingham Children's Hospital
-
Bristol、イギリス、BS2 8BJ
- University Hospitals Bristol & Weston NHS Foundation Trust
-
London、イギリス、WC1N 3HR
- Great Ormond Street Hospital for Children
-
London、イギリス、SE1 7EH
- Evelina London Children's Hospital - Haemophilia
-
-
-
-
-
Catania、イタリア、95123
- A.O.U policlinico "G. Rodolico-San Marco"
-
Florence、イタリア、50134
- Dipartimento di Ematologia Univ. Firenze
-
Padova、イタリア、35128
- Azienda Ospedaliera di Padova _
-
Parma、イタリア、43126
- Azienda Ospedaliera-Universitaria Parma
-
-
-
-
Assam
-
Guwahati、Assam、インド、781032
- Guwahati Medical College
-
-
Gujarat
-
Surat、Gujarat、インド、395002
- Nirmal Hospital Pvt. Ltd.
-
-
Maharashtra
-
Kolhāpur、Maharashtra、インド、416005
- SSSH_Dept. of Clinical Haematology & Haemato Oncology
-
Mumbai、Maharashtra、インド、400012
- Seth GS Medical College & KEM Hospital
-
Mumbai、Maharashtra、インド、400022
- K.J Somaiya Hospital and Research Centre
-
Mumbai、Maharashtra、インド、400066
- MCGM - Comprehensive Thalassemia Care
-
Pune、Maharashtra、インド、411004
- Sahyadri Super Speciality Hospital
-
-
Odisha
-
Cuttack、Odisha、インド、753007
- S.C.B. Medical College
-
-
Rajasthan
-
Jaipur、Rajasthan、インド、302004
- J K Lon Hospital
-
-
Uttar Pradesh
-
Noida、Uttar Pradesh、インド、201303
- Post Graduate Institute of Child Health
-
-
Uttart Pradesh
-
Lucknow、Uttart Pradesh、インド、226014
- SGPGI
-
-
-
-
-
Tallinn、エストニア、13419
- Tallinn Children's Hospital
-
-
-
-
British Columbia
-
Vancouver、British Columbia、カナダ、V6H 3V4
- BC Children's Hospital
-
-
Ontario
-
Hamilton、Ontario、カナダ、L8N 3Z5
- McMaster Children's Hospital
-
-
-
-
-
Athens、ギリシャ、GR-11527
- Aghia Sophia Childrens' Hospital
-
Thessaloniki、ギリシャ、GR 54642
- 'Ippokrateio' General Hospital of Thessaloniki
-
Thessaloniki、ギリシャ、54642
- 'Ippokrateio' General Hospital of Thessaloniki
-
-
-
-
-
Gothenburg、スウェーデン、413 46
- Sahlgrenska US - Koagulationscentrum
-
-
-
-
-
Barcelona、スペイン、08035
- Hospital Vall d'Hebron
-
Madrid、スペイン、28046
- Hospital Universitario La Paz
-
Málaga、スペイン、29009
- Hospital Regional Universitario de Málaga
-
-
Murcia
-
El Palmar、Murcia、スペイン、30120
- Hospital Virgen de la Arrixaca - Hematología
-
-
-
-
-
Bangkok、タイ、10400
- Ramathibodi Hospital
-
Bangkok、タイ、10330
- King Chulalongkorn Memorial Hospital_Bangkok_0
-
Bangkok、タイ、10700
- Siriraj Hospital - Hematology and Oncology
-
Bangkok、タイ、10330
- King Chulalongkorn Memorial Hospital_Pediatric Hematology-Oncology
-
-
Mueang Distirct,
-
Ubon Ratchathani、Mueang Distirct,、タイ、34000
- Sunpasitthiprasong Hospital_Pediatrics Department
-
-
-
-
-
Adana、トルコ(Türkiye)、01130
- Acibadem Adana Hastanesi
-
Adana、トルコ(Türkiye)、01130
- Acıbadem Adana Hastanesi-Hematoloji
-
Izmir、トルコ(Türkiye)、35100
- Ege Universitesi Tip Fakultesi
-
Izmir、トルコ(Türkiye)、35100
- Ege Üniversitesi Hastanesi- Hematoloji
-
Samsun、トルコ(Türkiye)、55139
- Ondokuz Mayis University Medical Faculty Ped. Haematology
-
Samsun、トルコ(Türkiye)、55139
- Ondokuz Mayıs Üniversitesi Hastanesi - Hematoloji
-
-
Beşevler/Ankara
-
Ankara、Beşevler/Ankara、トルコ(Türkiye)、06500
- Gazi University
-
Ankara、Beşevler/Ankara、トルコ(Türkiye)、06500
- Gazi Üniversitesi Hastanesi- Hematoloji
-
-
-
-
-
Oslo、ノルウェー、0372
- Klinisk forskningspost
-
-
-
-
-
Chambéry、フランス、73000
- Centre Hospitalier Metropole Savoie
-
Le Kremlin-Bicêtre、フランス、94275
- Ap-Hp-Hopital de Bicetre-1
-
Paris、フランス、75015
- AP-HP-HOPITAL NECKER_Service d'hématologie
-
-
-
-
-
Plovdiv、ブルガリア、4002
- UMHAT Sveti Georgi EAD, Plovdiv, Clinic of Pediatrics
-
Sofia、ブルガリア、1527
- UMHAT Tsaritsa Yoanna - ISUL EAD, Pediatric clinical hematology and oncology
-
Varna、ブルガリア、9010
- UMHAT Sveta Marina EAD, Clinic of Pediatric Clinical Hematology and Oncology
-
-
-
-
-
Banja Luka、ボスニア・ヘルツェゴビナ、78000
- University Clinical Center of Republic Srpska (545)
-
Tuzla、ボスニア・ヘルツェゴビナ、75000
- University Clinical Centre Tuzla
-
-
-
-
-
Gdansk、ポーランド、80-952
- Uniwersyteckie Centrum Kliniczne
-
Lublin、ポーランド、20-093
- Uniwersytecki Szpital Dzieciecy, Dzial Krwiolecznictwa
-
Warsaw、ポーランド、02-091
- Uniwersyteckie Centrum Kliniczne WUM
-
-
Lower Silesian Voivodeship
-
Wroclaw、Lower Silesian Voivodeship、ポーランド、50-556
- Uniwersytecki Szpital Kliniczny im. J.Mikulicza-Radeckiego
-
-
-
-
Kuala Lumpur
-
Kampung Baru、Kuala Lumpur、マレーシア、50300
- Hospital Tunku Azizah
-
-
Pulau Pinang
-
George Town、Pulau Pinang、マレーシア、10450
- Hospital Pulau Pinang
-
-
Sarawak
-
Kuching、Sarawak、マレーシア、93586
- Sarawak General Hospital
-
-
Terengganu
-
Kuala Terengganu、Terengganu、マレーシア、20400
- Hospital Sultanah Nur Zahirah
-
-
-
-
-
Vilnius、リトアニア、LT-08406
- Centre of Oncology and Hematology, Vilnius University
-
-
-
-
-
Bucharest、ルーマニア、022328
- Clinic of Haematology, Fundeni Clinical Institute
-
Cluj-Napoca、ルーマニア、400177
- Spitalul Clinic de Urgenta pentru Copii Cluj Napoca
-
Oradea、ルーマニア、410469
- Spitalul Clinic Judetean De Urgenta Bihor
-
-
-
-
-
Beirut、レバノン、961
- Saint George Hospital University Medical Center
-
Tripoli、レバノン、1434
- Hospital Nini
-
-
-
-
-
Skopje、北マケドニア、1000
- PHI University Clinic for Children's Diseases Skopje
-
-
-
-
Gauteng
-
Parktown, Johannesburg、Gauteng、南アフリカ、2193
- Charlotte Maxeke Johannesburg Academic Hospital
-
-
-
-
-
Kanagawa、日本、216-8511
- St. Marianna University School of Medicine Hospital_Pediatrics
-
Saitama、日本、330-8777
- Saitama Children's Med Centre_Hematology-Oncology
-
-
参加基準
適格基準
就学可能な年齢
- 子
- 大人
- 高齢者
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Informed consent/assent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
-
Diagnosis of congenital severe haemophilia A (FVIII below 1%) or moderate/severe congenital haemophilia B (FIX (coagulation factor IX) below or equal to 2%), or congenital haemophilia with inhibitors.
-
For arm 1 only: Male aged below 12 years of age at the time of signing informed consent.
-
For arm 1 only: Patients with inhibitors (haemophilia A with inhibitors or haemophilia B with inhibitors)
- Patients with HAwI (haemophilia A with inhibitors) with historical medical records of a total of at least 26 weeks of on-demand treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products) within the last 52 weeks prior to enrolment (For patients below 1 year of age that have been diagnosed with haemophilia <1 year prior to enrolment, historical medical records from time of diagnosis will suffice as long as medical records of a total of at least 26 weeks of relevant treatment is available).
- Patients with HBwI (haemophilia B with inhibitors) with historical medical records of a total of at least 26 weeks of on-demand treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products) within the last 52 weeks prior to enrolment (For patients below 1 year of age that have been diagnosed with haemophilia <1 year prior to enrolment, historical medical records from time of diagnosis will suffice as long as medical records of a total of at least 26 weeks of relevant treatment is available).
- Patients with HBwI regardless of the regimen and duration of previous haemophilia treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products)
-
For arm 1 only: Patients without inhibitors (haemophilia A or haemophilia B)
- Patients with historical medical records of at least 52 weeks of on-demand treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products; Surgery related PPX or short-term PPX (e.g., in relation to a severe bleed) is not allowed) during the last year prior to enrolment and with at least 3 documented treated bleeds (For participants less than (<) 2 years of age there is no limitation for number of documented treated bleeds in the medical history) during this period
- Patients with historical medical records of a total of at least 26 weeks of PPX (prophylaxis) treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products) within the last 52 weeks prior to enrolment (For patients below 1 year of age that have been diagnosed with haemophilia <1 year prior to enrolment, historical medical records from time of diagnosis will suffice as long as medical records of a total of at least 26 weeks of relevant treatment is available)
-
For arm 2 only: Male patients (regardless of age) previously treated with concizumab via compassionate use.
Exclusion Criteria:
- Known or suspected hypersensitivity to study intervention or related products.
- Known inherited or acquired coagulation disorder other than congenital haemophilia.
- Ongoing or planned Immune Tolerance Induction treatment.
- History of thromboembolic disease (aIncludes arterial and venous thrombosis including myocardial infarction, pulmonary embolism, cerebral infarction/thrombosis, deep vein thrombosis, other clinically significant thromboembolic events and peripheral artery occlusion.). Current clinical signs of or treatment for thromboembolic disease. Patients who in the judgement of the investigator are considered at high risk of thromboembolic events (Thromboembolic risk factors could include, but are not limited to, hypercholesterolemia, diabetes mellitus, hypertension, obesity, smoking, family history of thromboembolic events, arteriosclerosis, other conditions associated with increased risk of thromboembolic events).
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Concizumab-naïve patients
Concizumab-naïve participants below 12 years of age at the time of consent/assent |
Participants in Arm 1 will be assigned to concizumab prophylaxis starting with a loading dose on treatment day 0 followed by daily injections of an individual maintenance dose. Participants in Arm 2 will be assigned to concizumab prophylaxis with daily injections of an individual maintenance dose. |
|
実験的:Patients coming from compassionate use
Patients previously treated with concizumab via compassionate use, either on an individual patient basis or through the concizumab compassionate use programme NN7415-4807 |
Participants in Arm 1 will be assigned to concizumab prophylaxis starting with a loading dose on treatment day 0 followed by daily injections of an individual maintenance dose. Participants in Arm 2 will be assigned to concizumab prophylaxis with daily injections of an individual maintenance dose. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
時間枠:From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients treated on demand during at least the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
時間枠:From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of all bleeding episodes (spontaneous and traumatic)
時間枠:From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated spontaneous bleeding episodes
時間枠:From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated joint bleeding episodes
時間枠:From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated bleeding episodes in baseline target joints
時間枠:From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients treated on-demand during at least the last 52 weeks prior enrolment: Number of all bleeding episodes (spontaneous and traumatic)
時間枠:From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients treated on-demand during at least the last 52 weeks prior enrolment: Number of treated spontaneous bleeding episodes
時間枠:From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients treated on-demand at least the last 52 weeks prior enrolment: Number of treated joint bleeding episodes
時間枠:From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients treated on-demand at least the last 52 weeks prior enrolment: Number of treated bleeding episodes in baseline target joints
時間枠:From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
時間枠:From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of all bleeding episodes (spontaneous and traumatic)
時間枠:From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated spontaneous bleeding episodes
時間枠:From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated joint bleeding episodes
時間枠:From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated bleeding episodes in baseline target joints
時間枠:From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Concizumab-naïve pateints - Number of treatment emergent adverse events, reported both separately for inhibitor and non-inhibitor patients and combined
時間枠:From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of event(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Number of thromboembolic events, reported both separately for inhibitor and non-inhibitor patients and combined
時間枠:From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of event(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Number of hypersensitivity type reactions, reported both separately for inhibitor and non-inhibitor patients and combined
時間枠:From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of event(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Number of injection site reactions, reported both separately for inhibitor and non-inhibitor patients and combined
時間枠:From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of event(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Number of patients who develop antibodies to concizumab - yes/no, reported both separately for inhibitor and non-inhibitor patients and combined
時間枠:From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of patient(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Number of treatment emergent adverse events, reported both separately for inhibitor and non-inhibitor patients and combined
時間枠:From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of event(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Concizumab plasma concentrations prior to dosing, reported both separately for inhibitor and non-inhibitor patients and combined
時間枠:Week 32
|
Measured in ng/mL |
Week 32
|
|
Peak thrombin generation prior to dosing, reported both separately for inhibitor and non-inhibitor patients and combined
時間枠:Week 32
|
Measured in nM |
Week 32
|
|
Free TFPI concentration prior to dosing, reported both separately for inhibitor and non-inhibitor patients and combined
時間枠:Week 32
|
Measured in ng/mL |
Week 32
|
|
Pre-dose (trough) concizumab plasma concentration (Ctrough), reported both separately for inhibitor and non-inhibitor patients and combined
時間枠:Prior to the concizumab administration at week 20
|
Measured in ng/mL |
Prior to the concizumab administration at week 20
|
|
Maximum concizumab plasma concentration (Cmax), reported both separately for inhibitor and non-inhibitor patients and combined
時間枠:From 0 to 24 hours where 0 is the time of the concizumab dose at week 20
|
Measured in ng/mL |
From 0 to 24 hours where 0 is the time of the concizumab dose at week 20
|
|
Area under the concizumab plasma concentration-time curve (AUC), reported both separately for inhibitor and non-inhibitor patients and combined
時間枠:From 0 to 24 hours where 0 is the time of the concizumab dose at week 20
|
Measured in ng*hr/mL |
From 0 to 24 hours where 0 is the time of the concizumab dose at week 20
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Clinical Transparency (dept. 2834)、Novo Nordisk A/S
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- NN7415-4616
- U1111-1247-7330 (その他の識別子:World Health Organization (WHO))
- 2020-000504-11 (EudraCT番号)
- jRCT2031220097 (レジストリ識別子:JAPIC)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。